Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
AGL vs CVS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
AGL vs CVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Plans |
| Market Cap | $1.01B | $111.40B |
| Revenue (TTM) | $5.82B | $407.90B |
| Net Income (TTM) | $-373M | $2.93B |
| Gross Margin | -3.9% | 13.9% |
| Operating Margin | -6.8% | 1.5% |
| Forward P/E | — | 12.2x |
| Total Debt | $37M | $93.59B |
| Cash & Equiv. | $174M | $8.51B |
AGL vs CVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Agilon Health, Inc. (AGL) | 100 | 7.7 | -92.3% |
| CVS Health Corporat… (CVS) | 100 | 114.3 | +14.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AGL vs CVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AGL is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth -2.1%, EPS growth -55.6%, 3Y rev CAGR 35.4%
- Lower volatility, beta 2.98, Low D/E 29.0%, current ratio 1.02x
CVS carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- 3.5% 10Y total return vs AGL's -92.2%
- Beta 0.05, yield 3.1%, current ratio 0.84x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.8% revenue growth vs AGL's -2.1% | |
| Quality / Margins | 0.7% margin vs AGL's -6.4% | |
| Stability / Safety | Beta 0.05 vs AGL's 2.98 | |
| Dividends | 3.1% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +34.7% vs AGL's -28.4% | |
| Efficiency (ROA) | 1.1% ROA vs AGL's -24.5%, ROIC 5.0% vs -203.2% |
AGL vs CVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AGL vs CVS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CVS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CVS is the larger business by revenue, generating $407.9B annually — 70.1x AGL's $5.8B. CVS is the more profitable business, keeping 0.7% of every revenue dollar as net income compared to AGL's -6.4%. On growth, CVS holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $5.8B | $407.9B |
| EBITDAEarnings before interest/tax | -$366M | $10.5B |
| Net IncomeAfter-tax profit | -$373M | $2.9B |
| Free Cash FlowCash after capex | -$77M | $7.4B |
| Gross MarginGross profit ÷ Revenue | -3.9% | +13.9% |
| Operating MarginEBIT ÷ Revenue | -6.8% | +1.5% |
| Net MarginNet income ÷ Revenue | -6.4% | +0.7% |
| FCF MarginFCF ÷ Revenue | -1.3% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.3% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +140.0% | +63.1% |
Valuation Metrics
AGL leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.0B | $111.4B |
| Enterprise ValueMkt cap + debt − cash | $873M | $196.5B |
| Trailing P/EPrice ÷ TTM EPS | -2.48x | 62.81x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 12.19x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 13.11x |
| Price / SalesMarket cap ÷ Revenue | 0.17x | 0.28x |
| Price / BookPrice ÷ Book value/share | 7.92x | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | 14.27x |
Profitability & Efficiency
CVS leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CVS delivers a 3.9% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-146 for AGL. AGL carries lower financial leverage with a 0.29x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), CVS scores 5/9 vs AGL's 2/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -146.0% | +3.9% |
| ROA (TTM)Return on assets | -24.5% | +1.1% |
| ROICReturn on invested capital | -2.0% | +5.0% |
| ROCEReturn on capital employed | -108.4% | +6.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.29x | 1.24x |
| Net DebtTotal debt minus cash | -$137M | $85.1B |
| Cash & Equiv.Liquid assets | $174M | $8.5B |
| Total DebtShort + long-term debt | $37M | $93.6B |
| Interest CoverageEBIT ÷ Interest expense | -119.84x | 2.11x |
Total Returns (Dividends Reinvested)
CVS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVS five years ago would be worth $11,700 today (with dividends reinvested), compared to $724 for AGL. Over the past 12 months, CVS leads with a +34.7% total return vs AGL's -28.4%. The 3-year compound annual growth rate (CAGR) favors CVS at 11.0% vs AGL's -54.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +260.1% | +10.6% |
| 1-Year ReturnPast 12 months | -28.4% | +34.7% |
| 3-Year ReturnCumulative with dividends | -90.6% | +36.6% |
| 5-Year ReturnCumulative with dividends | -92.8% | +17.0% |
| 10-Year ReturnCumulative with dividends | -92.2% | +3.5% |
| CAGR (3Y)Annualised 3-year return | -54.6% | +11.0% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than AGL's 2.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs AGL's 50.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.98x | 0.05x |
| 52-Week HighHighest price in past year | $119.50 | $88.63 |
| 52-Week LowLowest price in past year | $0.97 | $58.35 |
| % of 52W HighCurrent price vs 52-week peak | +50.8% | +98.5% |
| RSI (14)Momentum oscillator 0–100 | 60.4 | 69.3 |
| Avg Volume (50D)Average daily shares traded | 373K | 7.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates AGL as "Hold" and CVS as "Buy". Consensus price targets imply 9.0% upside for CVS (target: $95) vs -59.6% for AGL (target: $25). CVS is the only dividend payer here at 3.06% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $24.50 | $95.20 |
| # AnalystsCovering analysts | 25 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | +3.1% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $2.67 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.3% | 0.0% |
CVS leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AGL leads in 1 (Valuation Metrics).
AGL vs CVS: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is AGL or CVS a better buy right now?
For growth investors, CVS Health Corporation (CVS) is the stronger pick with 7.
8% revenue growth year-over-year, versus -2. 1% for Agilon Health, Inc. (AGL). CVS Health Corporation (CVS) offers the better valuation at 62. 8x trailing P/E (12. 2x forward), making it the more compelling value choice. Analysts rate CVS Health Corporation (CVS) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AGL or CVS?
Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.
0%, compared to -92. 8% for Agilon Health, Inc. (AGL). Over 10 years, the gap is even starker: CVS returned +3. 5% versus AGL's -92. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AGL or CVS?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Agilon Health, Inc. 's 2. 98β — meaning AGL is approximately 5790% more volatile than CVS relative to the S&P 500. On balance sheet safety, Agilon Health, Inc. (AGL) carries a lower debt/equity ratio of 29% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — AGL or CVS?
By revenue growth (latest reported year), CVS Health Corporation (CVS) is pulling ahead at 7.
8% versus -2. 1% for Agilon Health, Inc. (AGL). On earnings-per-share growth, the picture is similar: Agilon Health, Inc. grew EPS -55. 6% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, AGL leads at 35. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AGL or CVS?
CVS Health Corporation (CVS) is the more profitable company, earning 0.
4% net margin versus -6. 8% for Agilon Health, Inc. — meaning it keeps 0. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CVS leads at 2. 6% versus -7. 1% for AGL. At the gross margin level — before operating expenses — CVS leads at 13. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is AGL or CVS more undervalued right now?
Analyst consensus price targets imply the most upside for CVS: 9.
0% to $95. 20.
07Which pays a better dividend — AGL or CVS?
In this comparison, CVS (3.
1% yield) pays a dividend. AGL does not pay a meaningful dividend and should not be held primarily for income.
08Is AGL or CVS better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Agilon Health, Inc. (AGL) carries a higher beta of 2. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, AGL: -92. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AGL and CVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AGL is a small-cap quality compounder stock; CVS is a mid-cap income-oriented stock. CVS pays a dividend while AGL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.